|drug123||Awake Proning Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
|D018352||Coronavirus Infections NIH||0.06|
There are 2 clinical trials
COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution to the lack of ICU beds and increasing deaths day after day. A recent retrospective Chinese paper (JAMA Intern Med, online March 13, 2020) showed impressive positive effect of methylprednisolone (MP) on survival of SARS-CoV-2 critically ill patients. Moreover, the Italian Infectious Disease leading institution guidelines for COVID-19 clinical management included as an option for patients with "incipient worsening of respiratory functions" methylprednisolone treatment at an approximate dose of 80mg. The main objective of this multi-centre observational trial is to analyse the association of low dose prolonged infusion of methylprednisolone (MP) for patients with severe acute respiratory syndrome with composite primary end-point (ICU referral, need for intubation, in-hospital death at day 28).
Description: We reported below the number of participants meeting at least one of three among death or ICU admission or Invasive mechanical ventilation.Measure: Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28 Time: 28 days
Description: We reported below the number of participants who died within 28 days, during the hospital stay.Measure: In-hospital Death Within 28 Days Time: 28 days
Description: We reported below the number of participants admitted to ICU within 28 days.Measure: Admission to Intensive Care Unit (ICU) Time: 28 days
Description: We reported below the number of participants who needed endotracheal intubation during ICU admissionMeasure: Endotracheal Intubation (Invasive Mechanical Ventilation) Time: 28 days
Description: Change in C-reactive protein after 7 days from baseline. A reduction of CRP reveals a laboratory improvement.Measure: Change in C-reactive Protein (CRP) Time: 7 days
Description: number of days free from mechanical ventilation (both invasive and non-invasive) by day 28Measure: Change in Duration of Mechanical Ventilation Time: 28 days
19 COVID (Coronavirus disease 2019 ) is a deadly viral disease that has been spreading around the world for several months, and is caused by a CORONA family virus (COVID-19). Following IN-VITRO evidence of the antiviral effect of CHLOROQUINE in CORONA viruses, this drug has been used empirically for COVID-19 patients and is currently recommended in Israel for the treatment of intermediate and severity disease. The mechanism of action of chloroquine is in part by inhibiting the virus distribution, and changing the intracellular acidity, the virus distribution site. The intracellular chloroquine concentration is determined by a pump called PGP (permeability glycoprotein) that removes the drug from the cell and is activated by the drug. In the treatment of malaria, the benefit of low dosage of the drug has been shown to be effective due to the fact that the intracellular concentration of the drug is probably higher, and therefore the logic to examine this issue in COVID-19 treatment. The purpose of this study is to test whether a low dose of Chloroquine will reduce the duration of the viral shedding and prevent the disease from worsening.
Description: change in the extent and duration of virus shedding.Measure: change in virus duration (viral shedding) Time: 23 days
Description: change in the number of patients going from asymptomatic to moderately diseaseMeasure: change in the number of patients going from asymptomatic to moderately disease Time: 1 month